Ottmann, Oliver G <br/><br/>
Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).  [electronic resource] 

 -  Cancer  May 2007 
 - 2068-76 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/cncr.22631  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Benzamides<br/>Disease-Free Survival<br/>Female<br/>Genes, abl<br/>Humans<br/>Imatinib Mesylate<br/>Male<br/>Middle Aged<br/>Piperazines--adverse effects<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrimidines--adverse effects<br/>Remission Induction<br/>Survival Rate